|Articles|September 1, 2003

Reimbursement Achievable for Biologics in Psoriasis

The January FDA clearance of Biogen Inc.'s Amevive (alefacept) for the treatment of moderate-to-severe chronic plaque psoriasis officially ushered in the era of biologic treatments for dermatologists.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe

Related Content

Understanding Immunologic Pathways Builds Clinician Confidence

ByEileen Cheever, MPAS, PA-C,Shannon Heaning, Content Associate

August 10th 2026

Are Private Dermatology Practices at Risk for Extinction? A New Survey Sheds Light

By Ashwin Krishnan,Shannon Heaning, Content Associate

June 30th 2026

The New Economics of Dermatology Claims: Understanding and Responding to Rising Denials

By Ashwin Krishnan,Matthew J. Elias, DO

June 23rd 2026

Contracts: The Most Important Document Most Clinicians Treat Like an Afterthought

ByJoseph Gatti, DMSc, MPAS, MBA, PA-C

May 28th 2026

Inside the Mind of NP and PA Candidates: What Employers Often Miss

ByJoseph Gatti, DMSc, MPAS, MBA, PA-C

April 3rd 2026

Latest CME

Video

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Video

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Multimedia

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Video

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Adaptive Learning

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Reimbursement Achievable for Biologics in Psoriasis

Related Content

Understanding Immunologic Pathways Builds Clinician Confidence

Are Private Dermatology Practices at Risk for Extinction? A New Survey Sheds Light

The New Economics of Dermatology Claims: Understanding and Responding to Rising Denials

Contracts: The Most Important Document Most Clinicians Treat Like an Afterthought

Inside the Mind of NP and PA Candidates: What Employers Often Miss

Latest CME

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Trending on Dermatology Times

Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension

Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease

Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine

Case Report Highlights Rural Care Gaps in Recurrent Merkel Cell Carcinoma

Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial